For in vitro diagnostic use. Others Elecsys Anti-HAV II IVD Elecsys® Anti-HAV II CPS_000191 04386159001 302818 ECL A-HAV Elecsys Anti-HAV II Reagents, kits 100 tests cobas e 411/601/602 09108882001 313500 ECL AHAV2 (E2G S300) Elecsys Anti-HAV II Reagents, kits 300 tests cobas e 801 08086664190 Anti-HAV G2 Elecsys E2G 300 Elecsys Anti-HAV II 07613336129715 Reagents, kits 300 tests cobas e 402/801 true 08086630190 Anti-HAV G2 Elecsys,cobas e100 Elecsys Anti-HAV II 07613336129722 Reagents, kits 100 tests cobas e 411/601/602 true 08086664500 Elecsys Anti-HAV II en 5 FF000000049CB90E FF0000000449590E 08086664190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro qualitative detection of total antibodies (IgG and IgM) to the hepatitis A virus (HAV) in human serum and plasma. The assay is used as an aid to detect a past or existing hepatitis A infection or used to determine the presence of antibody response to HAV in vaccine recipients.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08086664501 Elecsys Anti-HAV II en 2 FF00000004CAF60E FF00000003ACDE0E 08086664190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use Immunoassay for the in vitro qualitative detection of total antibodies (IgG and IgM) to hepatitis A virus (HAV) in human pediatric (ages 2 through 21 years) and adult serum and plasma (Li‑heparin, potassium EDTA, Na‑citrate, Na‑heparin). The assay, in conjunction with other serological and clinical information, is indicated as an aid in the clinical laboratory diagnosis of acute or past hepatitis A virus infection in persons with signs or symptoms of hepatitis and in persons at increased risk for hepatitis A infection, or as an aid to identify HAV susceptible individuals and to determine the presence of an antibody response to HAV in vaccine recipients. The electrochemiluminescence immunoassay “ECLIA” is intended for use on the cobas e immunoassay analyzers.Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients. This assay has not been FDA cleared or approved for the screening of blood or plasma donors. en 08086664501 Elecsys Anti-HAV II en 3 FF00000005C83A0E FF00000004CAF60E 08086664190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use Immunoassay for the in vitro qualitative detection of total antibodies (IgG and IgM) to hepatitis A virus (HAV) in human pediatric (ages 2 through 21 years) and adult serum and plasma (Li‑heparin, potassium EDTA, Na‑citrate, Na‑heparin). The assay, in conjunction with other serological and clinical information, is indicated as an aid in the clinical laboratory diagnosis of acute or past hepatitis A virus infection in persons with signs or symptoms of hepatitis and in persons at increased risk for hepatitis A infection, or as an aid to identify HAV susceptible individuals and to determine the presence of an antibody response to HAV in vaccine recipients. The electrochemiluminescence immunoassay “ECLIA” is intended for use on the cobas e immunoassay analyzers.Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients. This assay has not been FDA cleared or approved for the screening of blood or plasma donors. en 08086630500 Elecsys Anti-HAV II en 3 FF0000000460530E FF0000000384B70E 08086630190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro qualitative detection of total antibodies (IgG and IgM) to the hepatitis A virus (HAV) in human serum and plasma. The assay is used as an aid to detect a past or existing hepatitis A infection or used to determine the presence of antibody response to HAV in vaccine recipients.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08086630501 Elecsys Anti-HAV II en 1 FF00000003ACEC0E FF00000003ACEC0E 08086630190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use Immunoassay for the in vitro qualitative detection of total antibodies (IgG and IgM) to hepatitis A virus (HAV) in human pediatric (ages 2 through 21 years) and adult serum and plasma (Li‑heparin, potassium EDTA, Na‑citrate, Na‑heparin). The assay, in conjunction with other serological and clinical information, is indicated as an aid in the clinical laboratory diagnosis of acute or past hepatitis A virus infection in persons with signs or symptoms of hepatitis and in persons at increased risk for hepatitis A infection, or as an aid to identify HAV susceptible individuals and to determine the presence of an antibody response to HAV in vaccine recipients. The electrochemiluminescence immunoassay “ECLIA” is intended for use on the cobas e immunoassay analyzers.Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients. This assay has not been FDA cleared or approved for the screening of blood or plasma donors. en